Clinical Trials Browser

Phase 2/3 × INDUSTRY × nimotuzumab × Clear all

NCT01249352 2025-03-31

NICE

Phase 2/3 Completed

Gastrointestinal

Adenocarcinoma, Esophageal Neoplasms

NCT00561990 2015-10-15

Nimotuzumab in Adults With Pancreatic Cancer

Phase 2/3 Completed

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms